Publication: Liver stiffness improvement in hepatitis c patients after achieve sustained virologic response (SVR) 12 using APRI and FIB-4 score
No Thumbnail Available
Date
2021
Authors
Kamil, Mohd Firdaus Mohamad
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Chronic hepatitis C (CHC) is a major cause of liver mortality and morbidity. Direct Antiviral Agents (DAAs) have been shown to be effective. Obtaining a sustained virologic response after 12 weeks (SVR-12) of DAAs is critical in preventing fibrosis, disease progression (hepatocellular carcinoma) and clinical remission. This study aims to determine liver stiffness outcome using APRI and FIB-4 scores, as well as to determine the associated factors of liver stiffness outcome. Method: Study design was retrospective cohort, and the study involved a total of 180 patients from Hospital Sultanah Nur Zahirah, Kuala Terengganu. It involved adults above 18 years old and had achieved SVR-12 with DAAs (Sofosbuvir + Daclatasvir) regardless of treatment naivety or experience, presence of cirrhosis or virus genotype. They were evaluated using APRI and FIB-4 scores at the baseline and SVR-12. Results: APRI and FIB-4 scores were significantly associated with SVR-12 (P<0.05). The changes in mean (SD) APRI score were 1.58 (3.07) at baseline to 0.78 (1.07) after SVR- 12, while the mean (SD) FIB-4 score was from 3.40 (4.03) at baseline to 2.75 (2.97) after SVR-12. The multiple regression analysis revealed that clinical data including platelet, AST and ALT were significant predictors of advanced fibrosis (P<0.05). Conclusion: Our study has demonstrated a significant reduction in liver stiffness (based on APRI and FIB-4) after achieving SVR-12. Clinical data including platelet count and ALT and AST levels are significant independent predictors of liver fibrosis.
Description
Keywords
DAAs , Liver fibrosis